Reprint of “Pharmacokinetic modelling of the anti-malarial drug artesunate and its active metabolite dihydroartemisinin” by Hall, Adam J. et al.
c o m p u t e r m e t h o d s a n d p r o g r a m s i n b i o m e d i c i n e 1 1 4 ( 2 0 1 4 ) e14–e28
j o ur na l ho me  pag e: www.int l .e lsev ierhea l th .com/ journa ls /cmpb
Reprint  of  “Pharmacokinetic  modelling  of the
anti-malarial drug  artesunate  and  its  active
metabolite dihydroartemisinin”,
Adam J. Halla,∗, Michael J. Chappell b, John A.D. Astonc, Stephen A. Wardd
a Departments of Mathematics and Statistics, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK
b School of Engineering, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK
c Department of Statistics, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK
d Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 6 December 2012
Received in revised form
15  April 2013
Accepted 15 May 2013
Keywords:
Mathematical models
Biomedical systems
Drug kinetics
a  b  s  t  r  a  c  t
A four compartment mechanistic mathematical model is developed for the pharmacoki-
netics of the commonly used anti-malarial drug artesunate and its principle metabolite
dihydroartemisinin following oral administration of artesunate. The model is structurally
unidentiﬁable unless additional constraints are imposed. Combinations of mechanistically
derived constraints are considered to assess their effects on structural identiﬁability and on
model ﬁts. Certain combinations of the constraints give rise to locally or globally identiﬁable
model structures.
Initial validation of the model under various combinations of the constraints leading
to  identiﬁable model structures was performed against a dataset of artesunate and dihy-
droartemisinin concentration–time proﬁles of 19 malaria patients. When all the discussedStructural identiﬁability
Parameter estimation
Sensitivity analysis
constraints were imposed on the model, the resulting globally identiﬁable model structure
was  found to ﬁt reasonably well to those patients with normal drug absorption proﬁles.
However, there is wide variability in the ﬁtted parameters and further investigation is warr-
anted.
013 A
Artemisinin and its derivatives have been used as anti-©  2
1.  IntroductionMalaria is a parasitic disease that has affected humans and
animals for thousands of years [1]. Even now in the 21st cen-
tury, the most deadly strain Plasmodium falciparum infects 200
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million people and causes over half a million deaths every
year, with young children being most severely affected [2].eative Commons Attribution License, which permits unrestricted
al author and source are credited.
n purposes, please use the original publication details “Computer
malarials with increasing frequency since the 1990s [3].
They are the most rapidly acting drugs out of the currently
available anti-malarials [4], reducing the parasite biomass
er Ireland Ltd. All rights reserved.
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10, 000-fold per asexual life cycle [5,4]. They are well-
olerated and produce few side-effects [4], and as such form
he core part of the World Health Organisation recommended
rst-line treatment for many  patients: artemisinin-based
ombination therapies [2]. Artemisinins remain as the most
ffective drugs to which malaria has not yet developed
idespread resistance, though resistance has been conﬁrmed
n some regions [4]. It is hoped that use of these combination
herapies, in favour of artemisinin monotherapies, will assist
n delaying artemisinin resistance to ensure artemisinins con-
inue to remain effective against multi-drug resistant malaria
4]. Meanwhile, there remains an urgent need to develop new
ntimalarials [6].
However, the behaviour of current artemisinins is still not
ully understood; debate remains concerning their mecha-
ism of action [7,8] and stage-speciﬁc effects [9]. One theory
s that artemisinins decompose when activated by iron that
as accumulated in malaria infected red blood cells, form-
ng free radicals which then damage the parasites [10]. Thus
n this theory, the anti-malarial action also acts as a route of
limination for artemisinins.
Further, recrudescence is frequently observed with the
urrently adopted dosing regimens [11], which have been
erived largely empirically [4]. This recrudescence may be
ttributed to either resistant or arrested/dormant parasites, or
he drug concentrations in blood falling below their effective
evels, but such issues have not yet been fully characterised
9].
The blood plasma concentration–time proﬁles and thus
he pharmacokinetics of artemisinins have been shown
o display high inter-individual variability in the majority
f studies. Further understanding of the pharmacokinet-
cs and pharmacodynamics of artemisinins may assist
n informing more  effective dosing regimens, as well as
he development of improved antimalarials. This work
ocusses on the pharmacokinetics because a pharmacody-
amic model should build on a well-suited pharmacokinetic
odel.
Artesunate (hereafter ARS) is the most frequently used
rtemisinin derivative, and is rapidly and almost entirely con-
erted to dihydroartemisinin (hereafter DHA) in vivo, mostly by
lasma esterases and liver cytochrome P450 CYP2A6 [12–14].
HA is the most active of all artemisinin derivatives, with
ctivity approximately 1.4 times that of ARS [15].
ARS is water soluble, facilitating its absorption [16] (usu-
lly assumed to be fast, efﬁcient and ﬁrst-order [12]). Its
apid hydrolysis into the more  active metabolite means that
lthough ARS may make a signiﬁcant contribution to parasite
ill [17], it is often referred to as a pro-drug for DHA [3], and
ome researchers take the viewpoint that it is therefore not
ecessary to model the parent drug. DHA is also rapidly elim-
nated, again either through activation by infected red blood
ells or through further metabolism (e.g. glucuronidation [4]),
ut the metabolites of DHA are inactive [18].
Many  of the results and methods of studies involving ARS
nd DHA are summarised in Morris et al. [12], so no attempt is
ade to list them here. Instead, a brief discussion of existing
odels for artemisinin-class drugs in general, their features
nd the analyses conducted on them is provided in the next
ubsection.i o m e d i c i n e 1 1 4 ( 2 0 1 4 ) e14–e28 e15
1.1.  Existing  models
Many  existing pharmacokinetic studies for artemisinins have
been conducted over the last couple of decades, and have
successfully provided some insights into the absorption, elim-
ination and/or multiple dosing behaviour of these drugs,
and the covariates that inﬂuence these. Some studies have
restricted their interest to either healthy subjects, uncompli-
cated malaria, or severe malaria, and either children, adults or
pregnant women, while others have been designed speciﬁcally
to consider the differences between some of these groups.
Each study focusses on a speciﬁc artemisinin derivative or
derivatives, and a speciﬁc route or routes of administration,
either alone or in combination with other antimalarial agents.
Of those that used modelling rather than non-
compartmental approaches, some have been used to analyse
the effects of differing dosing regimens in different contexts,
including cases where the malaria has developed resistance
to this class of drugs [19]. They range from being very simple,
e.g. with linear absorption and exponential elimination as in
Saralamba et al. [19], to being quite complicated, e.g. involv-
ing 9 compartments as in Gordi et al. [20], and of various
complexities in between, e.g. 4 compartments as in Tan et al.
[21].
However, such models have not been analysed to deter-
mine if they are structurally identiﬁable. The importance of
knowing the structural identiﬁability of models will be reit-
erated in this paper. Indeed, Karunajeewa et al. [22] use a
three-compartment model based on mechanistic principles
but experience problems obtaining parameter estimates, per-
haps due to structural identiﬁability issues. In many  of the
more complicated models, there are even more  unknown
parameters and many  of these have to be assigned ﬁxed values
in order to estimate the remaining parameters successfully
(again perhaps due to structural identiﬁability issues). In those
cases, the selection of the parameters to ﬁx and what values to
use can be somewhat arbitrary and the effects of using other
values is not always explored or reported.
When processes involved in the system being modelled
are not well understood, it can be informative to perform
model selection based on comparing a relative goodness of
ﬁt statistic for a variety of structural models, and indeed this
approach is used to various extents for the pharmacokinetic
models used for artemisinins in the literature. However, when
information is known about the processes and mechanisms
involved, models selected in this way can be less useful than
models of process [23], and of course different models must be
used for different observational situations (e.g. Gordi et al. [20]
measure drug concentrations in saliva samples as opposed
to the more  common use of plasma samples, and so uses a
model tailored for that situation). To be fully certain of model
appropriateness, ﬁts should be reported and validated on an
individual patient basis in addition to any population lev-
els of interest. (If a mixed-effects/hierarchical model is used,
this means estimating the subject-speciﬁc deviation from the
mean parameters.) This can help to determine whether or not
there are key features of the data that are missed due to the
structure of the model employed, which may go unnoticed if
only population data are considered. However, pharmacoki-
netics on an individual patient basis are understandably of
e16  c o m p u t e r m e t h o d s a n d p r o g r a m s i n
Fig. 1 – System diagram of the general compartmental
model
mass, per kilogram of patient body weight (nmol/kg). Observa-
tions, which are concentrations, are assumed to be in units ofless interest than at population levels, and so attention typi-
cally focusses only on population ﬁts.
In summary, there are currently no known coupled mecha-
nistic pharmacokinetic models for artemisinin derivatives and
corresponding metabolites in vivo, with observations made of
the blood plasma concentrations of the administered deriva-
tives and their metabolites, that have either been analysed in
a structural identiﬁability sense or validated on an individual
patient basis.
2.  The  model
A relatively simple coupled mechanistic model was developed
for the pharmacokinetics of orally-administered ARS and its
principle metabolite DHA, for situations where blood plasma
concentrations of both are observed, and is depicted in Fig. 1.
It consists of four linked compartments, with the par-
ent drug and its metabolite each represented by two
compartments: an absorption (gut) compartment and a circu-
lation/plasma compartment. The absorption compartments
account for the delay in the drug and metabolite reaching the
circulation (and site of measurement) due to the oral route of
administration.
This differs structurally from the generic parent-
metabolite model with oral dose described by Cheung
et al. [24] (analysed for structural identiﬁability and applied
to dextromethorphan and dextrophan), which uses an extra
peripheral compartment for the parent drug and has a
direct ﬂow from its single absorption compartment to the
observed/central metabolite compartment.
The administered oral dose of ARS is considered as a bolus
(impulsive) input into its absorption compartment (1 in the
diagram). To account for bioavailability, a fraction b of the
administered dose D is assumed to reach the systemic circula-
tion. The dose D is prescribed in proportion to the body weight
of the patient, and so taken in units of nmol per kg.
Once in the system, ARS is either irreversibly metabolised
into DHA (compartment 3) prior to reaching the circulation
(compartment 4), or is absorbed into the circulation (compart-
ment 2) and subsequently metabolised (compartment 4 again).
Elimination can occur from any compartment except the input
compartment, and can be caused by either excretion from the b i o m e d i c i n e 1 1 4 ( 2 0 1 4 ) e14–e28
body or further metabolism into inactive metabolites which
are not of interest.
Observations are made of the drug concentrations in the
circulation compartments, with observation gains ˛1 for ARS
(y1) and ˛2 for DHA (y2). These parameters incorporate the vol-
umes of distribution of the respective drugs. As is standard for
the purposes of assessing the identiﬁability of the structural
model, it is assumed that observations are made continually
over the entire inﬁnite time horizon, and are made without
error. These two assumptions are relaxed later when dealing
with the problem of parameter estimation from data.
Note that because metabolism of ARS into DHA  takes
place in the liver as well as in esterases, metabolism can
occur before presentation in the observed circulation com-
partments. Indeed, in concentration–time proﬁles of malaria
patients (e.g. those analysed in this work), large quantities of
DHA are observed in the blood plasma prior to those of ARS,
which cannot be attributed solely to being artefacts of differ-
ing observation gains (or otherwise to quantiﬁcation limits).
Hence, the presence of compartment 3 is crucial to capture
the metabolism-before-absorption route that ARS can take.
The differential equation characterisation of the model is
given, for t ∈ [0, ∞)  describing the time in hours since drug
administration, by
⎧⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎩
q′(t) = Aq(t) + Bu(t)
q(0+) = q0
y(t) = Cq(t).
(1)
Here, q = (q1 q2 q3 q4)T represents the state vector of the
system model, where each qi denotes the quantity of the
respective drug in compartment i, u(t) = (Dı(t)  0 0 0)T denotes
the model input and q0 = (0 0 0 0)T the initial condition, y
denotes the vector-valued observation function, and the
model matrices are
A =
⎛
⎜⎜⎜⎜⎝
−(k21 + k31) 0 0 0
k21 −(k42 + ke2) 0 0
k31 0 −(k43 + ke3) 0
0 k42 k43 −ke4
⎞
⎟⎟⎟⎟⎠ , (2a)
B =
⎛
⎜⎜⎝
b
0
0
0
⎞
⎟⎟⎠ , C =
(
0 ˛1 0 0
0 0 0 ˛2
)
. (2b)
Note that there are different ways to parameterise u, q0 and
B. The parameterisation used here has been chosen as it more
clearly corresponds to the mechanistic concepts.
Due to the difference in the molecular weights of the parent
drug and the metabolite, the qi are considered in units of molarnmol/l. The observation gains ˛1 and ˛2 therefore have units of
kg/l, but the volumes of distribution are generally assumed to
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cale approximately linearly with patient body weight, hence
he reason that the dosing is calculated in those terms.
All ﬂows  (absorption, metabolism and elimination) are
ssumed to be ﬁrst-order and linear, with rate constants kij
denoting the ﬂow rate constant to compartment i from com-
artment j, or to the environment when i = e) time-invariant
nd speciﬁed in units of per hour (which are standard units for
rtemisinin drugs). Note that conversion into inactive unmea-
ured metabolites and excretion from the body are considered
s ﬂows to the environment with respect to the system model.
The system of equations (1), with u(t) and q0 as described
bove, can easily be solved analytically to yield:
(t) = bDeAt, y(t) = Cq(t). (3)
The solution for the state variables is thus
q1(t) = bDe−(k21+k31)t
q2(t) =
bDk21
(
e−(k42+ke2)t − e−(k21+k31)t
)
k21 + k31 − k42 − ke2
q3(t) =
bDk31
(
e−(k43+ke3)t − e−(k21+k31)t
)
k21 + k31 − k43 − ke3
q4(t) = bD
(
e−(k21+k31)t
k221k42 + k31k43(k31 − k42 − ke2) + k21(k31(k42 + k43) − k42(k43 + ke3))
(k21 + k31 − k42 − ke2)(k21 + k31 − k43 − ke3)(k21 + k31 − ke4)
− e
−(k42+ke2)tk21k42
(k21 + k31 − k42 − ke2)(k42 + ke2 − ke4)
− e
−(k43+ke3)tk31k43
(k21 + k31 − k43 − ke3)(k43 + ke3 − ke4)
+ e
−ke4 t(k31k43(k42 + ke2 − ke4) + k21k42(k43 + ke3 − ke4))
(k21 + k31 − ke4)(k42 + ke2 − ke4)(k43 + ke3 − ke4)
)
.
(4)
.  Structural  identiﬁability
efore attempting to apply this model to real data for parame-
er estimation, it is necessary to check that all the parameters
re theoretically identiﬁable from “perfect data” (noise-free
ata available over the entire inﬁnite time horizon assum-
ng no model misspeciﬁcation), in the sense that they can
ither be uniquely determined or there are only a countable
umber of alternative parameter combinations with identi-
al input/output structure. This is the structural identiﬁability
roperty, and is an important property to check in order to
nderstand what kinds of inferences can validly be made
bout the parameters in the model. For an unidentiﬁable
odel, a good ﬁt to data does not imply that the estimated
arameters have any connection to the intended interpreta-
ions, which may invalidate model predictions and in turn
ause important decisions in terms of dosing regimens to be
ade incorrectly.
Let p denote the vector of unknown parameters in theodel. Take
 =
(
b k21 k31 k42 k43 ke2 ke3 ke4 ˛1 ˛2
)T
, (5)i o m e d i c i n e 1 1 4 ( 2 0 1 4 ) e14–e28 e17
where the feasible parameter space is  : = (0, ∞)n  p, with
n = 10 denoting the number of unknown parameters.
The observation function y is now written y(· , p) to empha-
sise its dependence on the unknown parameters.
3.1.  Structural  identiﬁability  deﬁnitions
Structural identiﬁability is the measure theoretic concept of
local injectivity of the observation function with respect to the
model parameters, excepting sets of parameter values with
measure zero.
A component parameter pi of p is said to be
• structurally locally identiﬁable (SLI) iff for almost every
p ∈ , there exists a neighbourhood N(p) ⊆  of vectors
around p such that
if p¯∈ N(p) and y(·, p) = y(·, p¯)
then p¯i = pi;
(6)
• structurally unidentiﬁable (SUI) otherwise.
If N(p) =  can be used in (6) for almost every p, then pi is also
said to be structurally globally identiﬁable (SGI).
The structural identiﬁability of the whole model is deﬁned
in terms of the structural identiﬁability of the unknown
parameters as follows:
• The model is structurally locally identiﬁable iff all parameters
in p are at least structurally locally identiﬁable;
• The model is structurally unidentiﬁable iff any of the param-
eters in p are structurally unidentiﬁable.
If all the parameters in the model are also structurally glob-
ally identiﬁable then the model itself is said to be structurally
globally identiﬁable.
Note that structural identiﬁability depends on each of the
feasible parameter space, the system model structure, the
observations and the inputs.
3.2.  Analysis  for  present  model
The structural identiﬁability of this model was analysed using
the Laplace transform approach [25], one of the most com-
monly used methods for linear time-invariant systems.
This method considers the Laplace transforms of the
observation functions after eliminating the state variables.
It extracts the coefﬁcients of the resulting expressions once
written in a standard form, with common factors in each
respective numerator and denominator cancelled. These
coefﬁcients are assembled in a vector (p) as an “exhaustive
summary” of observational parameters [26]. The injectivity
condition of the full observation function vector is equiva-
lent to that of the exhaustive summary, and the latter has the
advantage of being easier to work with.
The Laplace transforms of the observation functions y1(· ,
p) and y2(· , p) are given (in their simplest forms), for s ∈ C, by
Y1(s, p) = 1(p)
s2 + 2(p)s + 3(p)
, (7a)
 s i ne18  c o m p u t e r m e t h o d s a n d p r o g r a m
Y2(s, p) = 4(p)s + 5(p)
s4 + 6(p)s3 + 7(p)s2 + 8(p)s + 9(p)
, (7b)
where the coefﬁcients depending on p form the exhaustive
summary and are given by
1(p) = ˛1bDk21 (8a)
2(p) = k21 + k31 + k42 + ke2 (8b)
3(p) = (k21 + k31)(k42 + ke2) (8c)
4(p) = ˛2bD(k21k42 + k31k43) (8d)
5(p) = ˛2bD(k21k42(k43 + ke3) + k31k43(k42 + ke2)) (8e)
6(p) = k21 + k31 + k42 + k43 + ke2 + ke3 + ke4 (8f)
7(p) = (k21 + k31)(k42 + k43 + ke2 + ke3 + ke4)
+ ke4(k42 + k43 + ke2 + ke3) + (k42 + ke2)(k43 + ke3) (8g)
8(p) = ke4(k21(k42 + k43 + ke2 + ke3) + k31(k42 + k43 + ke2 + ke3)
+ (k42 + ke2)(k43 + ke3)) + (k21 + k31)(k42 + ke2)(k43 + ke3) (8h)
9(p) = ke4(k21 + k31)(k42 + ke2)(k43 + ke3). (8i)
Using the Laplace transform approach, the structural (local)
identiﬁability problem is to determine whether, for generic p,
the only solution (in a neighbourhood of p) to the system of
equations
1(p) = 1(p¯) (9a)
2(p) = 2(p¯), (9b)
... (9c)
9(p) = 9(p¯) (9d)
is
p = p¯. (10)
The symbolic computer package Maple (version 16) was
used to solve this system of equations. Mathematica (ver-
sion 8.0.1) failed to solve this system of equations on an
Intel Core i5 2.40 GHz machine with 2.8 GB of memory  before
exhausting the available memory  after 30 min, whereas Maple
comfortably solved the system within 2 min  on the same
machine.
It is readily observed (e.g. from the Laplace coefﬁcients) that
b, ˛1 and ˛2 are not structurally identiﬁable individually, since
they appear only as the products b˛1 and b˛2. In what follows,
b˛1 and b˛2 are therefore considered to be combined parame-
ters. Hence, the set of unknown parameters is now taken as
p = ( k21 k31 k42 k43 ke2 ke3 ke4 b˛1 b˛2 )
T
, b i o m e d i c i n e 1 1 4 ( 2 0 1 4 ) e14–e28
(so with n = 9 unknown parameters) and the structural identi-
ﬁability analysis proceeds in this setting.
Solving the system of equations (3.2) reveals that ke4 is
SLI with either ke4 = ke4 or ke4 = k43 + ke3, and all other model
parameters are SUI. As there is little point working with a SUI
model, the following additional assumptions were therefore
considered to see if they constrain the system model to be
structurally identiﬁable:
1 Other studies have reported apparent volumes of distribu-
tion for ARS and DHA following oral administration of ARS.
In particular, Morris et al. [12] report the median volume
of distribution for ARS at 6.8 l/kg and 1.55 l/kg for DHA in
malaria patients (though these are noted to vary signiﬁ-
cantly relative to severity of infection). Such information
can be used to treat the ratio of the observation gains as
known; that is, r : = ˛2/˛1 is known (˛1 =  ˛ and ˛2 = r˛,
say). Using the above information from Morris et al.
[12], this would give r = 4.387 (the observation gain for
DHA is larger because it has the smaller volume of
distribution);
2 There is no known reason to suggest that the metabolism
of the ARS occurs at signiﬁcantly different rates before
and after absorption, so it might be valid to consider the
metabolism rate constants to be equal: k31 = k42;
3 ARS is almost entirely converted to DHA (there are little
excreted traces of ARS or its other metabolites), so it may be
reasonable to assume that the elimination rate parameter
ke2 = 0;
4 Absorption of the metabolite is rapid, thus its elimination
may be negligible before it is absorbed, i.e. ke3 = 0.
Note that when constraints of this sort are imposed on
parameters, the corresponding models are considered to be
structurally distinct; structural identiﬁability is concerned
with the behaviour of almost all parameter values, and these
assumptions may mean that previously null sets now have
strictly positive measure.
Each combination of these four assumptions was assessed
using the same methods as previously, and the structural
identiﬁability results are tabulated in Table 1. It can be
seen that applying just one of the additional constraints
does not improve the structural identiﬁability for the major-
ity of the parameters. Applying any combination of two
constraints except ˛2/˛1 = r and ke2 = 0 constrains all the
parameters to be at least structurally locally identiﬁable.
Applying any combination of three of the assumptions
constrains the model to be structurally globally iden-
tiﬁable. The assumption (2) that k31 = k42 seems to be
the weakest in terms of improving structural identiﬁabil-
ity.
Parameter estimates will be obtained with all four assump-
tions imposed, as it the strongest situation in terms of
structural identiﬁability, and the fewer degrees of freedom
will aid in more  precise estimation of parameters. Parameter
estimates will also be obtained with other structurally identi-
ﬁable combinations of assumptions, to assess the sensitivity
to the assumptions and to ensure that the system is not over-
constrained.
c o m p u t e r m e t h o d s a n d p r o g r a m s i n b i o m e d i c i n e 1 1 4 ( 2 0 1 4 ) e14–e28 e19
Table 1 – Structural identiﬁability analysis results
Assumptions Structural identiﬁability results
˛2
˛1
= r, r known k31 = k42 ke2 = 0 ke3 = 0 k21 k31 k42 k43 ke2 ke3 ke4 b˛1 b˛2 b˛
0 0 0 0 U U U U U U L U U –
0 0 0 1 U U U L U – L U U –
0 0 1 0 U U L U – U L U U –
0 0 1 1 L L L L – – L L L –
0 1 0 0 U – U U U U L U U –
0 1 0 1 L – L L L – L L L –
0 1 1 0 G – G L – L L G L –
0 1 1 1 G – G G – – G G G –
1 0 0 0 U U L U L U L – – U
1 0 0 1 L L L L L – L – – L
1 0 1 0 U U G U – U G – – U
1 0 1 1 G G G G – – G – – G
1 1 0 0 L – L L L L L – – L
1 1 0 1 G – G G G – G – – G
1 1 1 0 G – G G – G G – – G
1 1 1 1 G – G G – – G – – G
The applicable parameters under any combination of the assumptions (1 if the assumption is applied and 0 if not) are either structurally
loball
4
4
T
f
c
B
a
p
b
s
o
1
a
w
i
f
B
d
1
4
ﬁ
q
i
c
s
Q
d
o
a
a
s
(unidentiﬁable (U), structurally locally identiﬁable (L) or structurally g
.  Parameter  estimation
.1.  Data
he authors had access to a dataset of 19 malaria patients
rom a study carried out at the Department of Clinical Tropi-
al Medicine, Faculty of Tropical Medicine, Mahidol University,
angkok, 10400, Thailand. Patients were selected based on
 diagnosis of adult non-severe P. falciparum malaria with a
arasite count less than 10,000 parasites per microlitre of
lood. The patients were each administered 2 mg/kg arte-
unate in fractions of 50 mg oral tablets (body weights not part
f the dataset) twice daily for three days, in combination with
800 mg  fosmidomycin and 750 mg  azithromycin which are
ntibiotics and not considered relevant to the modelling. Food
as restricted for the ﬁrst hour after dosing.
The data consist of ARS and DHA concentrations (provided
n units of ng/ml but converted to nmol/l prior to analysis)
rom assayed blood plasma samples over a time course of 12 h.
lood plasma samples were drawn from the patients imme-
iately after administration of the ﬁrst dose on the ﬁrst day,
5 min  after, 30 min  after, 1 h after, 1.5 h after, 2 h after, 3 h after,
 h after, 6 h after, 8 h after and 12 h after administration of the
rst dose on the ﬁrst day. No samples were taken for subse-
uent doses or on subsequent days and so cannot be included
n the modelling.
Samples were analysed to determine their ARS and DHA
oncentrations using tandem liquid chromatography-mass
pectrometry (on a Thermo Fisher Quantum Access Triple
uad Mass Spectrometer) based on the assay described in Lin-
egardh et al. [27]. (The individual samples were analysed only
nce but assay robustness was conﬁrmed by a re-analysis of
pproximately 10% of all samples. Analytical runs included full calibration curve and three replicate quality control
amples.)
The assay has an associated lower limit of quantiﬁcation
LLOQ) for each analyte and passed FDA validation, for whichy identiﬁable (G).
the requirement is to measure quality control samples and
standard curve samples with known concentrations above the
respective LLOQ to within ±15% of the nominal value. Specif-
ically, the coefﬁcient of variation for the assay is 15% for both
analytes. Values below the respective LLOQ may have signif-
icantly greater relative uncertainty or noise. The LLOQ for
ARS was LLOQ1 = 3.9 nmol/l and that of DHA  was LLOQ2 = 22.9
nmol/l. The assumption is that values reported for unknown
samples above the respective LLOQ will also be within 15%
of the actual value. Observations below the respective LLOQ
are felt to be so unreliable that such values are not quantiﬁed;
they are only reported as being below the limit of quantiﬁca-
tion (BLQ). In this way, 41% of the ARS data and 8% of the DHA
data are censored.
Note that over the 12 h time span for a single subject, a wide
range of drug concentrations was observed, most particularly
for DHA. Speciﬁcally, for DHA, concentrations smaller than
the LLOQ and concentrations above 6000 nmol/l were recorded
for some patients over the course of the sampling interval. In
common with other studies, there was also wide variability
between patients in terms of the concentration–time proﬁles
for both ARS and DHA.
The majority of the patients had peak ARS concentra-
tions within 1.5 h after drug administration (74%), and peak
DHA concentrations within 2 h (63%). However, it was already
clear from the data that over half of the patients experienced
delayed or possibly double peaks in the concentration–time
proﬁles for both ARS and DHA. These are not thought to be
outliers due to the assay validation, and the pattern is quite
consistent in some individuals. There are no covariates with
these data to allow further analysis and the cause of this
phenomenon is not known, nor the frequency of incidence
in other artesunate studies as individual patient proﬁles are
often not discernible. The only reference to this issue in rela-
tion to artemisinin drugs that the authors are aware of is to the
derivative artemether, which was found by Van Agtmael et al.
[28] to have a biphasic absorption proﬁle. As the mechanistic
 s i ne20  c o m p u t e r m e t h o d s a n d p r o g r a m
cause of the phenomenon is unknown, the differences in the
absorption process have not been accounted for in the present
model. This indicates that the model is misspeciﬁed and will
not be suitable for all the patients, though it is hoped that it
will still be applicable for many  of the patients.
The patients were therefore divided into two groups, one
where the concentration–time proﬁles for both ARS and
DHA exhibited only a single peak each within the expected
time after drug administration, and the other group for the
remaining patients where the absorption proﬁle was unex-
pected, e.g. being slower to reach the peak concentrations,
having multiple peaks and/or having delayed elimination.
Model ﬁts and validation will therefore be separately described
for each of the two groups.
For illustration, consider Fig. 2. The concentration–time
proﬁles for both drugs for patient A were as expected, so this
patient was placed in the ﬁrst group. Patient B, however, clearly
has an unusual concentration–time proﬁle (and it is not clear
whether it is just caused by random measurement error) and
so was placed in the second group. The proﬁles for patient C
exhibited later peaks (and thus delayed DHA elimination), and
was also placed in the second group.
4.2.  Statistical  treatment  of  data
At this stage, the structural model is now considered with
error (for a single patient), and the observations are now ﬁnite
in number and collected at discrete times. Only measurement
error is considered, as error resulting from model misspeciﬁ-
cation is assumed to be dominated by measurement error.
So, let y˜i denote the ith observation of drug di (0 = ARS, 1
= DHA) and ti denote the time at which this observation was
made. Then,
y˜i = hi(p) + i,
where hi(p) = max{ydi (p, ti), LLOQdi } is the model prediction of
the ith observation and i denotes the observation error (and
ydi is as in (1)).
Statistically, it is assumed that the measurement error is
normally distributed, so a measured value of y˜i is assumed
to be an observation from a N(hi(p), 2i ) distribution where
i = ıhi(p) with ı = 0.15. Equivalently, i∼N(0, 2i ). It is
further assumed that the observation errors for observations
at different times are independent. (This assumption may not
be realistic but was felt to be a good starting point in the
absence of any prior information to the contrary.) Observation
errors for ARS and DHA observations obtained at the same
time are assumed to be correlated with correlation parameter
 unknown.
Note that this error model does not account for the fact
that the observed concentrations will always be positive, but
is nevertheless convenient to work with.
Observations below the respective LLOQ may be caused by
no drug being present at all, the drug quantity being close to
the LLOQ itself, or any range in between. Values below the
LLOQ are treated as being at the LLOQ here, as this simpliﬁes
their statistical treatment, and this method was shown to pass
certain tests for suitability, described shortly.
It is convenient to view the y˜i as forming a one-dimensional
vector. Write y˜  for the data and h(p) for their model b i o m e d i c i n e 1 1 4 ( 2 0 1 4 ) e14–e28
predictions. The above speciﬁcation gives rise to the follow-
ing log-likelihood function, deﬁned up to an additive arbitrary
constant:
(p|y˜) = −1
2
(log det V(p) + (y˜ − h(p))TV(p)−1(y˜ − h(p))︸  ︷︷ ︸
weighted residual sumof squares (WRSS)
),
(11)
where V(p) is the weighting matrix with (i, i)-th element 2
i
and (i, j)-th element ij when ti = tj, i /= j. Note that with this
deﬁnition, the residuals y˜i − hi(p) are zero for those points i
where the model prediction and corresponding datum both
lie below the LLOQ.
Similarly to Bergstrand and Karlsson [29], this methodol-
ogy was ﬁrst tested on simulated data to determine how well
it copes with the censored aspect. First, using simulated data
with known parameter values, with and without censoring
and error, model ﬁtting was conducted to see how reliably and
closely the original parameter values were reproduced. This
included omitting BLQ values from the ﬁtting, treating them
as described above, and by assuming BLQ values are known
with the same error distribution as the other data. Second,
real data were used with the above described procedure, and
by omitting BLQ values, and the corresponding ﬁts compared.
In each case, parameter estimates and ﬁtted curves did not sig-
niﬁcantly differ with the different methodologies. Further, in
the simulated data case, the original parameters were closely
recovered.
4.3.  Estimation  procedure  and  parameter  uncertainty
Standard numerical optimisation methods were used to ﬁnd
a minimiser pˆ  of the negative of the log-likelihood expres-
sion (hereafter referred to as the objective function), and the
minimiser was used as an estimate of the parameters. See
e.g. Seber and Wild [30]. This optimisation was carried out in
Mathematica using the NMinimize function.
To attempt to quantify the uncertainty in the parameter
estimates, the asymptotic (for a large number of observations)
distribution of the parameter estimates was found [30]. This
technique is appropriate even if pˆ is only a local minimiser of
the objective function, rather than a global minimiser.
The asymptotic distribution of the parameter estimate pˆ
is approximately MVN (p*, C) where MVN denotes the multi-
variate normal family of distributions, p* is the “true” value
of p and the variance-covariance matrix C is described next.
Consider the linear approximation to the dependence of the
unweighted residuals on the parameters about the estimate
pˆ:
R(pˆ) = ∂
∂pT
(y˜ − h(p))|p=pˆ. (12)
The inverse of the Fisher information matrix at pˆ provides an
estimate C of the asymptotic variance-covariance matrix for
pˆ,
C = (R(pˆ)TV(pˆ)−1R(pˆ))−1. (13)
c o m p u t e r m e t h o d s a n d p r o g r a m s i n b i o m e d i c i n e 1 1 4 ( 2 0 1 4 ) e14–e28 e21
Fig. 2 – Example of observed ARS and DHA plasma concentrations (nmol/l) for three patients. Error bars represent ±15% of
the observations and are representative of the assay error (for reasons discussed in Section 4.2).
r
r
c
i
tThe variance-covariance matrix C is easier to interpret by
eporting the diagonal elements of C together with the cor-
elation matrix formed by dividing the respective rows and
olumns by the square roots of these diagonal elements. This
nformation fully speciﬁes C but is easier to compare and con-
rast than C itself.4.4.  Goodness  of  ﬁt  statisticsLikelihood function values and WRSS values are not directly
comparable between patients, due to each data set having
a different variation to begin with. Instead, the (weighted)
coefﬁcient of determination can be used. Loosely speaking, this
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Table 2 – Fitted parameter values, aggregated
Parameter Mean (SD) Units
b  ˛ 0.4723 (0.3205) kg/l
r 4.3870 (ﬁxed) Dimensionless
k21 0.2806 (0.2987) h−1
k42 1.1185 (0.7436) h−1
k43 0.8347 (0.5908) h−1
ke4 1.6123 (1.2848) h−1
CoD weighted 74.2505 (28.8048) %
ARS half-life 0.9283 (0.5778) he22  c o m p u t e r m e t h o d s a n d p r o g r a m
expresses the variation in the data explained by the model as
a ratio of the total variation present in the data, and is deﬁned
as
R2:=100
(
1 − (y˜ − h(p))
TV(p)−1(y˜ − h(p))
(y˜ − y¯)TV(p)−1(y˜ − y¯)
)
%, (14)
where the elements of y are the average of the observed values
for the corresponding curve.
The idea is that a larger coefﬁcient of determination should
indicate a better ﬁt. However, a large value of this statistic
does not necessarily correspond to a high likelihood, which
is in some ways problematic, but it does accord at least qual-
itatively with a visual analysis of ﬁts. (Note that the baseline
model is simply a mean model, which is not contained in the
ﬁtted model class, so the ANOVA interpretation of this statistic
does not apply.)
4.5.  Results:  individual  ﬁts
Due to the wide range in concentrations reported for individ-
ual patients over the studied time interval, parameter ﬁtting
using the weighting matrix corresponding to the reported
errors did not yield good ﬁts. When using errors corresponding
to predicted observations, high concentrations were artiﬁ-
cially predicted, corresponding to low weights. These points
could thus be missed completely with little penalty on the
likelihood. Prior to conducting the analysis, this symptom
was expected and it was planned that the condition num-
ber of the weighting matrix might need to be controlled to
resolve this. The singular values of the weighting matrix (to
cater for the cases where the matrix was not diagonal due
to the assumption of correlation between different measure-
ment errors) were therefore capped so that no singular value
exceeded 100 times the lowest singular value, resulting in
the condition number of the weighting matrix becoming at
most 100. Imposing this cap yielded much improved model
ﬁts.
Even with this cap, the objective function had multiple
local minima for many  patients, and often had multiple
local minima achieving similar objective function values
but considerably different parameter estimates. In these
cases, the global minimum was usually selected, except
in a minority of cases where the ﬁtted parameter values
were extreme and a local minimum seemed more  realistic.
This highlights the fact that having a globally identiﬁable
model structure is a necessary but not sufﬁcient condition
to ensure robust parameter estimation from sampled data,
especially in the presence of high model and observation
errors.
Observations and model ﬁts for the three patients whose
proﬁles were shown previously are presented in Fig. 3 (patient
A), Fig. 4 (patient B) and Fig. 5 (patient C), together with
model predictions of the quantities in the absorption com-
partments, and estimated parameter values with measures of
their uncertainty. The conﬁdence bands give an indication of
the sensitivity of the ﬁt and are explained and discussed in
the following section.
It can be seen that the model ﬁt for patient A appears to
be satisfactory. It is difﬁcult to determine whether the ﬁt forDHA half-life 0.7156 (0.5304) h
patient B is reasonable or not because the concentration–time
proﬁles observed are unusual, and may or may not be a result
of random measurement error. The ﬁt for patient C is unsatis-
factory because the model cannot account for the later peaks
due to the model misspeciﬁcation mentioned earlier. The con-
ﬁdence bands for patient C also clearly indicate a problem with
the model.
For brevity, results for the other patients are not pre-
sented here in the same way, but instead model ﬁt results
are summarised through the coefﬁcient of determination and
shown in Fig. 6, and a summary of parameter estimates
across all patients is provided in Table 2. The worst model
ﬁts correspond to patients whose observed ARS and DHA
concentration–time proﬁles did not both reach peaks within
3 h of dose administration, or those where at least one of
the drugs exhibited multiple peaks (approximately half of the
patients exhibited one of these issues, and are coloured in red
in Fig. 6). Note that the ﬁt for one such patient has a neg-
ative coefﬁcient of determination. This does not necessarily
suggest that ﬁtting the mean to the concentration–time pro-
ﬁle of each drug would have performed better than ﬁtting the
model (although that is a natural interpretation), because the
model still captures part of the absorption and elimination
processes and therefore their shapes, though model predic-
tions should not be relied upon in these circumstances. The
coefﬁcient of determination statistic was used to help quantify
the goodness of the model ﬁts, but it is not without prob-
lems and should not be considered the sole determinant of
the result.
The ﬁts were typically insensitive to the correlation param-
eter  (perhaps as a result of the weight cap) and this
parameter was often ﬁtted close to 0 even when not used as
the initial value for the optimisation. Having preferred a local
minimum over the global minimum in some cases, no indi-
vidual parameter estimates were unreasonable in isolation.
However, the parameter estimates were not always consid-
ered well determined and many  varied signiﬁcantly between
patients. This was most marked for k21, where the largest
and smallest estimated values differed by a factor of 100,
while the other parameters varied by roughly a factor of 10.
The wide variability in the patient proﬁles makes it possi-
ble that (though unclear whether) this is plausible, and could
be due to differences in the severity of the malaria, issues
with the quality of the data, or other covariates (such covari-
ates were not available for evaluation here). These issues
will be explored further in the following section, “Sensitivity
analysis”.
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Fig. 3 – Example of model predicted ARS and DHA quantities/concentrations in each compartment for patient A, with table
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Many  people working in the ﬁeld prefer to express elimina-
ion parameters in terms of half-lives. From the parameters in
he parameter vector p, the ARS half-life can be calculated as
1
2 ,ARS
= ln 2/(k42 + ke2), (15)
nd the DHA half-life as
1
2 ,DHA
= ln 2/ke4. (16)Estimates of these parameters obtained here (shown in
able 2) agree in range with those summarised in Morris
t al. [12] (0.36–1.2 h for ARS and 0.49–3.08 h for DHA), butror bars are representative of assay error.
while Morris et al. [12] report that the DHA half-life is con-
sistently longer than that of ARS, the same result was not
found for all the patients in this study; the reasons for this
are unclear.
Model ﬁtting was also conducted by relaxing one constraint
at a time (still resulting in SGI model structures) to assess
the effect on the parameter estimates. Doing so either did
not signiﬁcantly alter the parameter estimates, or otherwise
did not generally improve ﬁts visually (sometimes making
them appear noticeably worse), and only marginally reduced
the objective function values. The resulting estimates for
some parameters were very close to their constrained val-
ues in some cases, while in others, the parameter estimates
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Fig. 4 – Example of model predicted ARS and DHA quantities/concentrations in each compartment for patient B, with table
ly, erof parameter estimates and their uncertainties. As previous
changed signiﬁcantly and inconsistently, and their associated
uncertainties increased also. When this occurred, the changes
propagated to the other parameters too (due to the correla-
tion), resulting in even wider variability of the parameters
between patients. These results therefore provide evidence
suggesting that the constraints imposed are as reasonable as
could be hoped.5.  Sensitivity  analysis
A sensitivity analysis was also carried out to assess how well-
determined the parameter estimates are (with the exceptionror bars are representative of assay error.
of the nuisance parameter ), and the effects of slight pertur-
bations of parameters on model predictions. This informs on
how accurately it is possible to determine the parameters and
how accurately it is necessary to determine them.
The statistical parameter correlation matrices reported
together with the parameter estimates contain sensitivity
information. They indicate by how much changes in any given
parameter will affect the other parameters if the ﬁts are to
remain similar. Pairs of parameters which are highly cor-
related and parameters with high standard errors may be
difﬁcult to estimate numerically. Many pairs of the parame-
ters have high correlations, with absolute values above 0.80,
and this is one possible explanation for some of the issues
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Fig. 5 – Example of model predicted ARS and DHA quantities/concentrations in each compartment for patient C, with table
of parameter estimates and their uncertainties. As previously, error bars are representative of assay error.
Fig. 6 – Distribution of the coefﬁcient of determination (%)
over the dataset; marks in red correspond to patients with
unexpected proﬁles. Recall that the objective was not to
maximise the coefﬁcient of determination, but this statistic
allows easier comparison between subjects than the actual
objective function values.encountered with the parameter estimation described in the
previous section.
The ﬁtted parameters have an asymptotic multivariate
normal distribution centred around the ﬁtted values, with
variance given approximately by the corresponding dispersion
matrix (the matrix formed by the combination of the correla-
tions and the standard errors), and this parameter distribution
gives rise to distributions revealing the local uncertainty
around the ﬁtted curves. Monte Carlo techniques were used
to estimate the 10th and 90th percentiles of the latter distri-
butions, and the regions between these two percentiles form
the pointwise conﬁdence/prediction bands illustrated in the
plots.
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While it has already been noted that this model is not suit-
able for all patients, particularly due to the issues with the
peaks, in many  cases where the issue is prominent, the conﬁ-
dence bands indicate that there is an issue with the model (as
observed for patient C).
A further analysis was also carried out using normalised
(ﬁrst-order) sensitivities, considering the whole time domain
of interest instead of just the observational times as in the
statistical results. The sensitivity of a dependent variable x
to a change in the parameter pj (considered about parameter
vector pˆ) is the local quantity given by [31,32]
sx,pj := (
∂x
∂pj
)
∣∣∣∣
pˆ
,
but for comparing between different parameters, the following
semi-normalised form is preferred [33]:
Sx,pj := (pj
∂x
∂pj
)
∣∣∣∣
pˆ
,
which has the same units as x. Note that this formulation nor-
malises only by the presence of the pj, and does not divide by
x itself (unlike as in [31,32]) to facilitate interpretation in an
identiﬁability and correlation sense.Note that if the variable x is a function of an independent
variable—such as time as here—then so are its sensitivities
(Sx,pj ). It is therefore useful to summarise each as a single
value, in addition to visualising them as graphical plots over
Fig. 7 – Normalised sensitivity plots for the model about the esti
observations and then the unobserved compartments b i o m e d i c i n e 1 1 4 ( 2 0 1 4 ) e14–e28
the relevant domains. A natural summary is the mean of the
absolute value of the sensitivity function,
Sx,pj :=
1
12
∫ 12
0
|Sx,pj (t)|dt. (17)
If the shapes of curves (exclusive of direction and scale)
for the sensitivities of multiple parameters are similar for
all observation variables, or if any parameters have low
normalised sensitivities, numerical identiﬁability of those
parameters will be difﬁcult. In this case, if the curves for the
corresponding model predictions are not also similar, inability
to identify the parameters numerically will have a signiﬁcant
effect on the predictions.
While sensitivity depends on the estimated parameters
and so is a local property, when applied to the model presented
here, the sensitivity for different patients at their respective
parameter estimates were very similar in shape, only with dif-
ferences in scale; therefore only patient A is reported in full
detail. The graphical plots for the normalised sensitivities for
patient A are collected in Fig. 7 together with their means as
described above. As the observation gain for the observed cir-
culation compartments does not have any relevance to the
predicted quantities in the absorption compartments, note
that b  ˛ has no inﬂuence on the latter, which has to be con-
sidered modulo the unidentiﬁable bioavailability factor b.
Recall from earlier that not all parameters were consid-
ered well determined by the data for a number of patients.
mated parameters for patient A, ﬁrst with respect to the
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his can now be explored in more  depth. Subjects for which
uch issues were observed had high standard deviation esti-
ates for the problem parameter(s), and had corresponding
ormalised sensitivities relating to the observed quantities an
rder of magnitude lower than that shown for patient A. In
ome cases, when the observations are insensitive to a param-
ter, the model predictions are similarly insensitive to it as
ell. Therefore, even though the parameter cannot be esti-
ated to a high degree of conﬁdence in such circumstances,
t is not necessary for it to be known with high precision
o maintain model utility. On the other hand, there were
ome parameters to which the unobserved quantities were
qually or more  sensitive than the observed quantities, and
he model is of limited use when these parameters cannot
e estimated with conﬁdence, such as in the case of patient
.
.  Conclusion
 novel feature of the proposed model is that it accounts
or the possibility that some of the orally administered par-
nt drug ARS is metabolised into DHA before it is completely
bsorbed, e.g. as a ﬁrst-pass effect. This is consistent with
revious reports in the literature. Just as the pharmacokinet-
cs of ARS and DHA differ widely between individuals, so too
o the goodness of ﬁts and parameter estimates under this
ew model. Model ﬁts appeared to be reasonably good for a
umber of patients, but the concentration–time proﬁles for
ertain patients did not ﬁt the usual absorption behaviour,
nd model ﬁtting was less satisfactory for some of these
atients.
The authors are currently looking into those data sets
here double peaks were apparent, and further investigation
s also needed with more  extensive datasets. If this phe-
omenon is observed elsewhere and conﬁrmed to be distinct
rom random measurement error, the authors would like to
etermine a more  appropriate mechanistic model under these
ircumstances. Future work also includes consideration of
ptimal design measures and performing a random effects
nalysis for the subjects—a kind of population analysis, where
arameters are estimated using all individual data sets, allow-
ng the parameters to borrow support across all individual
ata sets while still providing separate ﬁts for each individual
atient.
An important inﬂuencing factor in the pharmacokinetics of
he artemisinin drugs is the severity of the malaria infection
n the subject. Speciﬁcally, the disposition and effectiveness
f artemisinin drugs very much depends on the number of
arasites within each of the developmental forms (ring forms,
oung trophozoites, mature trophozoites and schizonts, etc.)
uring the therapeutic window, as each stage has a different
rtemisinin susceptibility and the pharmacodynamic action
s a route of elimination for these drugs. Reduced ring form
usceptibility is also thought to be an important effect of par-
site resistance to artemisinins [19]. Therefore, the authors are
urrently investigating pharmacokinetic/pharmacodynamic
odels incorporating the lifecycle of the parasites where
he drugs affect the parasites and the parasites affect the
rugs.i o m e d i c i n e 1 1 4 ( 2 0 1 4 ) e14–e28 e27
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